mTOR Inhibition and Kidney Diseases

Area of Science:

• Nephrology
• Molecular Biology
• Pharmacology

Background:

• The mammalian target of rapamycin (mTOR) pathway regulates critical cellular functions including growth, proliferation, metabolism, and survival.
• Aberrant mTOR pathway activation is implicated in various kidney diseases, including renal transplant rejection, autosomal dominant polycystic kidney disease, renal cell carcinoma, diabetic nephropathy, lupus nephritis, and angiomyolipoma.

Purpose of the Study:

• To review the current understanding of the mTOR signaling pathway in both physiological and pathological kidney conditions.
• To summarize recent findings on the use of mTOR inhibitors in managing kidney transplantation and non-transplant kidney diseases.

Main Methods:

• Literature review of studies on mTOR signaling and its inhibitors in kidney diseases.
• Analysis of data from basic, animal, and clinical studies.

Main Results:

• mTOR inhibitors like sirolimus and everolimus are used in immunosuppression for renal allograft rejection.
• Preclinical data suggest potential benefits of mTOR inhibitors in autosomal dominant polycystic kidney disease and other renal diseases by reducing hypertrophy, inflammation, and fibrosis.
• Clinical translation of these benefits for non-transplant kidney diseases remains challenging.

Conclusions:

• The mTOR pathway is a significant factor in kidney health and disease.
• mTOR inhibitors show promise in managing kidney transplant rejection and potentially other renal conditions, but further clinical research is needed for broader application.